Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

Transplant Proc. 1997 Feb-Mar;29(1-2):809-11. doi: 10.1016/s0041-1345(96)00143-1.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Azathioprine / therapeutic use
  • Costs and Cost Analysis
  • Cyclosporine / therapeutic use
  • Cytomegalovirus / isolation & purification*
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Infections / economics
  • Cytomegalovirus Infections / prevention & control*
  • Follow-Up Studies
  • Ganciclovir / adverse effects
  • Ganciclovir / therapeutic use*
  • Graft Rejection / epidemiology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation* / economics
  • Morbidity
  • Polymerase Chain Reaction / methods*
  • Postoperative Complications*
  • Prednisone / therapeutic use
  • Sensitivity and Specificity
  • United States
  • Viremia / diagnosis
  • Viremia / economics
  • Viremia / epidemiology

Substances

  • Antilymphocyte Serum
  • Antiviral Agents
  • Immunosuppressive Agents
  • Cyclosporine
  • Azathioprine
  • Ganciclovir
  • Prednisone